New molecular entity NDAs up in FY 2004
Executive Summary
The number of new molecular entity submissions to FDA increased slightly in fiscal year 2004. FDA received 28 NME submissions in FY 2004 (ended Sept. 30), up from 25 NMEs in FY 2003 and 22 the prior year. NME submissions still have not climbed back to the level of three to five years ago. The agency received 32 NMEs in FY 2001, 30 in 2000 and 37 in 1999. BLA submissions spiked in 2004 with 20 new applications, up from eight in 2003. Nine BLAs were submitted in 2002 and eight in 2001...
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.